AND Haemolysis persists after at least 14 days of conventional corticosteroid therapy unless steroid therapy is contra-indicated AND Splenectomy is contraindicated or Immunosuppression is contraindicated It was that there are a very small number of patients on maintenance therapy Maintenance therapy for AIHA in patients and it was agreed that this needed to be unsuitable for Splenectomy or immunosuppression accommodated provided patients met the criteria as now defined. SWG advised that a Symptomatic or severe AIHA with current 6 month initial review was required with the option to continue treatment ongoing where Haemoglobin less than 60g/L (unless significant patients remained transfusion dependant comorbidities exist) requiring ongoing and symptomatic (A) transfusion support for at least two months AND Haemolysis persists after at least 14 days of conventional corticosteroid therapy unless steroid therapy is contra-indicated AND Splenectomy is contra-indicated or Immunosuppression is contra-indicated. To reduce haemolysis in patients with AIHA not Given that dosing is mostly one-off, outcome Resolution of haemolytic anaemia (rising Review Criteria data may be entered but will not be responding to corticosteroid therapy haemoglobin concentrations, falling mandatory. SWG did not consider the Review is not mandated for this indication however original outcome measures as defined to be bilirubin and LDH). the following criteria may be useful in assessing the robust. The capture of bilirubin and LDH effectiveness of therapy. Clinical improvement in symptoms and levels was not endorsed. Review criteria for assessing the effectiveness of Ig signs. use when one-off treatment is
AND Haemolysis persists after at least 14 days of conventional corticosteroid therapy unless steroid therapy is contra-indicated AND Splenectomy is contraindicated or Immunosuppression is contraindicated Maintenance therapy for AIHA in patients unsuitable for Splenectomy or immunosuppression Symptomatic or severe AIHA with current Haemoglobin less than 60g/L (unless significant comorbidities exist) requiring ongoing transfusion support for at least two months AND Haemolysis persists after at least 14 days of conventional corticosteroid therapy unless steroid therapy is contra-indicated AND Splenectomy is contra-indicated or Immunosuppression is contra-indicated. It was that there are a very small number of patients on maintenance therapy and it was agreed that this needed to be accommodated provided patients met the criteria as now defined. SWG advised that a 6 month initial review was required with the option to continue treatment ongoing where patients remained transfusion dependant and symptomatic (A) Review Criteria Resolution of haemolytic anaemia (rising haemoglobin concentrations, falling bilirubin and LDH). Clinical improvement in symptoms and signs. To reduce haemolysis in patients with AIHA not responding to corticosteroid therapy Review is not mandated for this indication however the following criteria may be useful in assessing the effectiveness of therapy. Review criteria for assessing the effectiveness of Ig use when one-off treatment is Given that dosing is mostly one-off, outcome data may be entered but will not be mandatory. SWG did not consider the original outcome measures as defined to be robust. The capture of bilirubin and LDH levels was not endorsed.
autoimmune-haemolytic-anaemia-aiha.DOCX